As of Wednesday, December 17, EUDA Health Holdings Limited’s EUDA share price has surged by 5.42%, which has investors ...

Medline, a medical-supplies manufacturer and distributor, raised $6.26 billion in its initial public offering, notching the largest IPO since 2021. The Blackstone- and Carlyle\-backed company sold 216 ...

Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...

Compare QQQ vs ARKK: discover key investment strategies, risk profiles, and why QQQ is rated Buy for stability.

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

Intellia Therapeutics finds itself navigating turbulent waters, with its stock price hitting fresh lows as a combination of clinical setbacks and insider sel ...

These companies could innovate their way to success.

Shares of gene-editing company Intellia Therapeutics continue to struggle under significant pressure. This follows the U.S. Food and Drug Administration's (FDA) decision to halt the firm's most ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

According to Precedence Research, the global gRNA market size is expected to grow from USD 708.92 million in 2025 to nearly ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...